Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: A prospective, randomized, multicenter study

Chinese Medical Journal

Volumn 126, Issue 15, 2013, Pages 2805-2809

  Li, Ning Chen ^a   Ye, Zhang Qun ^b   Na, Yan Qun ^a  

^a PEKING UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Instillation therapy; Non muscle invasive bladder cancer; Pirarubicin; Randomized clinical trial

Indexed keywords

PIRARUBICIN; THP; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER IRRITATION; CHINA; CONTROLLED STUDY; CYSTALGIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SIDE EFFECT; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; URINARY FREQUENCY; URINARY URGENCY;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84880948786     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131042     Document Type: Article

References (20)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-477.
2. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996; 155: 1233-1238
3. Brausi M, Collette L, Kurth K. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523-531.
4. Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002; 42: 167-174.
5. Kanayama H, Yokota K, Kurokawa Y, Kagawa S, Yokozeki H, Inai T, et al. Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer. Jpn J Cancer Chemother 1999; 26: 651-655.
6. Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, et al. Randomized study of single early instillation of (2"R)-4'- O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002; 94: 2363-2368.
7. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57: 766-773.
8. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-2190.
9. Ali-El-Dein B, Nabeeh A, El-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumors: prospective, randomized controlled study. Br J Urol 1997; 79: 731-735.
10. Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 2004; 46: 336-338.
11. Li NC, Xiao YX, Song Y, Zhang K, Yuan JF, Gong K, et al. Intravesical instillation of pirarubicin for preventing postoperative recurrence of superficial bladder cancer in 132 patients. Chin J Clin Oncol (Chin), 2005; 32: 1245-1247.
12. Zhu YP, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, et al. A meta-analysis of the efficacy of intravesical instillation of pirarubicin in preventing recurrence of non-muscle invasive bladder cancer. Chin J Clin Oncol (Chin) 2009; 36: 1294-1295.
13. Jin FS, Lan WH, Zhang Y, Wang LF. An efficacy comparison of pararubicin with other intravesical chemotherapeutic agents in preventing bladder tumor recurrence: a Meta-analysis. Chin J Urol (Chin) 2009; 30: 685-688.
14. Li NC, Xie LP, Chen LW, Dong SG, Fan XR, Pan TJ, et al. Guidelines on diagnosis and treatment of bladder cancer. In: Na YQ, Sun G, eds. Chinese Urological Association Guidelines on diagnosis and treatment of urological diseases in China. Beijing: People's Medical Publishing House; 2011: 17-48.
15. Takao M, Nagakura K, Shimizu S, Kawabata K, Kimura F, Sawamura M, et al. Absorption of tetrahydropyranyl adriamycin administered intravesically immediately after transurethral resection of bladder carcinoma. Hinyokika Kiyo 1990; 36: 1163-1166.
16. Yamamoto Y, Nasu Y, Saika T, Akaeda T, Tsushima T, Kumon H. The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. BJU In 2000; 86: 802-804.
17. Mei HB, Wang F, Chang JP, Zhang ZL, Shi M, Ye SB, et al. A comparative study of immediately intravesical instillations of pirarubicin combined with conventional intravesical instillations for preventing postoperative recurrence of superficial bladder cancer. J Clin Urol 2010; 25: 536-538.
18. Tian XQ, Xing NZ, Wang Y, Li JX. The effectiveness of early intravesical instillation after TURBt for preventing recurrence of bladder cancer. J Clin Urol 2006; 21: 4-6.
19. Gudjónsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009; 55: 773-780.
20. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011; 186: 2158-2167.